Collegium Pharmaceutical has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026 for redemption on Friday, June 14, 2024. The redemption price will be
Collegium Pharmaceutical has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026 for redemption on Friday, June 14, 2024. The redemption price will be
STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has called all $26,350,000 aggregate principal amount of its outstanding 2.625%
In a report released today, Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical (COLL – Research Report), with a price target of $40.00. I’m sorry, but I
Truist raised the firm’s price target on Collegium Pharmaceutical to $40 from $37. The company’s Q4 results were “solid” with record topline and EBITDA but uneventful following its earlier pre-announcement,
Truist העלו את מחיר היעד שלהם עבור Collegium Pharmaceutical ל-40 ליש”ט, מ-37 ליש”ט. הם ציינו כי תוצאות הרבעון הרביעי של החברה היו חזקות, עם ההכנסה הגבוהה ביותר אי פעם ו-EBITDA